# 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy

> **NCT07747493** · NA · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 8 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)
- Localized Prostate Cancer

## Interventions

- **DRUG:** Gallium Ga 68 Gozetotide (68Ga-PSMA-11)
- **DIAGNOSTIC_TEST:** Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions

## Key facts

- **NCT ID:** NCT07747493
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07747493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07747493, "68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07747493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*